Celljevity’s Path to Being Public: What Retail Investors Need to Know About Clinical-Stage Biotech Listings

This article is for educational purposes only and does not constitute investment advice. Prospective investors should consult qualified financial professionals and review official offering documents before making investment decisions. Investing in clinical-stage biotechnology companies carries substantial risk, including potential loss of entire investment.The Biotech IPO Window ReopensThe biotechnology IPO market demonstrated renewed vitality in 2024, producing 25 biotech listings compared to 19 in 2023, r ...